Advertisement · 728 × 90
#
Hashtag
#Q1Profit
Advertisement · 728 × 90
Preview
Sony hikes annual profit forecast by 4%, citing smaller trade war impact TOKYO (Reuters) -Sony raised its full-year operating profit forecast on Thursday by 4% to 1.33 trillion yen ($9.01 billion), citing a diminished impact from U.S. President Donald Trump’s trade war. In May, Sony (NYSE:SONY) forecast a profit of 1.28 trillion yen, factoring in a 100 billion yen hit from the tariffs. The Japanese conglomerate has transformed from a maker of household electronics such as the Walkman to an entertainment behemoth spanning games, movies, music and chips. ($1 = 147.5700 yen)

Click Subscribe #Sony #Q1Profit #EarningsReport #StockMarket #Investing

0 0 0 0
Preview
Panasonic Energy Q1 profit grows 47% year-on-year on AI boom TOKYO (Reuters) -Panasonic on Wednesday said first-quarter operating profit at its battery-making unit grew 47% as an AI investment boom offset the negative impact of U.S. tariffs and the termination of electric vehicle tax credits. Profit at the unit, which makes batteries for Tesla (NASDAQ:TSLA) and other EV makers, rose to 31.9 billion yen ($215.6 million). Concerns remain over a further slowdown in EV demand due to U.S. tariff policies and the termination of the IRA 30D tax credit, Panasonic (OTC:PCRFY) said in a presentation slide, but noted that demand for energy storage systems for data centres is "growing more than anticipated". For the full-year ending in March 2026, the company maintained its operating profit forecast for the energy unit of 167 billion yen. However, Panasonic Group Chief Financial Officer Akira Waniko said on a conference call that it "seems inevitable" that its projection of 46 gigawatt hours (GWh) for EV battery sales in North America for the fiscal 2025/26 year will be downscaled. It should at least surpass fiscal 2024/25’s 38.1 GWh, Waniko added. Panasonic Holdings said in May it would cut 10,000 staff and expected to book restructuring costs of 130 billion yen as part of a push to improve group profitability. The electronics manufacturer said at the time it did not expect to book any restructuring costs in its energy business. Last week, Panasonic Energy’s major customer Tesla warned of fallout from the U.S. government’s legislation to cut a $7,500 tax credit for EV buyers. Panasonic Energy operates a plant in the U.S. state of Nevada that provides batteries to Tesla and earlier this month started production at its second U.S. plant, in Kansas. It also makes energy storage systems for data centres in its consumer business, which in the April-June quarter saw a rapid rise in demand owing to massive AI-related investments, the company said. But both auto batteries and consumer energy storage systems would see a certain impact from U.S. President Donald Trump’s tariffs, it said, adding it would offset additional tariff costs by price revisions. Panasonic Energy is investing in new battery technologies as it competes with Chinese and South Korean rivals such as CATL and LG Energy Solution (LGES) in the global EV supply chain. ($1 = 147.9400 yen) With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is TSLA one of them?

Click Subscribe #Panasonic #Energy #Q1Profit #AIBoom #Investing

0 0 0 0
Preview
Teva Pharmaceutical’s branded drugs boost first quarter profit JERUSALEM (Reuters) - Teva Pharmaceutical Industries (NYSE:TEVA) reported a larger than expected rise in first-quarter profit, helped by strong sales gains for a trio of its branded drugs treating migraines, Huntington’s disease and schizophrenia. The world’s largest generic drugmaker, Teva is relying on these and other innovative drugs to drive growth and help it raise its operating margin by four points to 30% by 2027. "Two years ago, nobody thought Teva could do anything in innovation," chief executive Richard Francis told Reuters. "What we’re seeing now ... shows whether it’s the US, Europe or international markets, we’re really good at innovative R&D and innovative commercialization." Francis said generics remains a key pillar of its growth strategy and Teva plans a number of copycat launches along with biosimilars in the next two years. Teva said on Wednesday it earned 52 cents per diluted share, excluding one-time items, in the January-March quarter, up from 48 cents a share a year earlier. Revenue rose 2% to $3.89 billion. Analysts had forecast earnings of 46 cents per share ex-items for the Israel-based company on revenue of $3.99 billion, LSEG I/B/E/S data showed. Growth was led by a 39% rise in sales of Huntington’s disease drug Austedo, a 26% gain in migraine medicine Ajovy and a 156% jump in schizophrenia treatment Uzedy. Teva expects Austedo sales of $1.95-$2.05 billion in 2025, with Ajovy hitting around $600 million and Uzedy at $160 million. Overall, Teva sees 2025 revenue of $16.8-$17.4 billion, with adjusted earnings per share of $2.45-$2.65, up from a prior estimate of $2.35-$2.65. The company noted its net debt fell to $15 billion and that it expects net savings of $700 million by 2027. Francis said that Teva’s strong manufacturing footprint in the United States should enable it to avoid damage from potential U.S. tariffs. Teva’s New York listed shares rose 7.3% to $17.29 by late morning trade. "That ... reinforces our view that Teva is well-positioned for sustained multiple expansion," he said.

Click Subscribe #TevaPharmaceuticals #Pharmaceuticals #Biotech #Healthcare #Q1Profit

0 0 0 0
Preview
Obesity drugmaker Novo Nordisk cuts 2025 outlook, posts Q1 profit above forecast COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk (NYSE:NVO) on Wednesday cut its full-year sales and profit outlook amid lacklustre U.S. prescription data and posted first-quarter operating profit above analyst forecasts. "In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments," CEO Lars Fruergaard Jorgensen said in a statement. "However, we have reduced our full-year outlook due to lower than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the U.S.," he said. The Danish company cut its guidance and now expects 2025 sales growth in local currencies of between 13% and 21%, compared to the 16%-24% range given at the beginning of the year. Novo reported first-quarter earnings before interest and taxation (EBIT) of 38.79 billion Danish crowns ($5.90 billion), compared with the 37.20 billion forecast in a company-compiled consensus based on 26 analysts and up 22% from a year ago. NVO: A Bull or Bear Market Play? Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if NVO is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #NovoNordisk #ObesityDrug #Pharmaceuticals #Q1Profit #StockMarket

0 0 0 0
Preview
Shell Q1 profit drops 28%, but beats expectations LONDON (Reuters) -Shell on Friday reported a 28% drop in first-quarter net profit to $5.58 billion, beating analyst expectations, and kept the pace of its share buyback programme steady amid falling oil prices and lower refining margins than last year. It said it would buy back $3.5 billion worth of shares for the next three months, the fourteenth consecutive quarter of a buyback programme of at least $3 billion. That contrasts with rival BP (NYSE:BP), which has sharply cut its buybacks this year to shore up its balance sheet. Shell’s gearing, a debt-to-equity ratio, of 18.7% is less than BP’s 25.7%. Shell’s adjusted earnings, its definition of net profit, reached $5.58 billion in the first quarter, above an average forecast of $4.96 billion in a company-provided analyst poll, but below $7.73 billion a year ago. At a strategy update in March, Shell pledged to return more cash to shareholders on the back of higher liquefied natural gas sales, mainly via buybacks, trimmed its investments through 2028 and raised the prospect of selling or closing some chemicals assets. The company on Friday reiterated its reduced annual investment budget of $20-$22 billion for this year. Its indicative refining margin stood at $6.2 per barrel, down from $12 per barrel a year ago, but up from $5.5 per barrel at the end of last year. Global benchmark Brent crude prices averaged around $75 a barrel during the January-March quarter, compared with around $87 a year earlier. Shell said its gas trading business was in line with the previous quarter despite a hit from expiring hedging contracts. That contrasts with BP, which said that a weak result in its gas trading business weighed on its first-quarter results.

Click Subscribe #Shell #Q1Profit #EarningsReport #StockMarket #Investing

0 0 0 0

Click Subscribe #StanChart #Q1Profit #WealthManagement #BankingGrowth #FinancialNews

0 0 0 0
Preview
Nasdaq beats Q1 profit estimates on market volatility, strong product demand (Reuters) -Nasdaq beat first-quarter profit expectations on Thursday as the exchange operator benefited from higher market volatility and strong demand for its fintech and solutions products, sending its shares up 1% before the bell. Total U.S. equity options volumes jumped to 935 million contracts in the quarter, compared to 773 million contracts in the same quarter last year. To diversify its revenue streams, the company has been expanding outside its market-sensitive core activities of trading and listing to products that help financial institutions navigate compliance requirements and safeguard against financial crimes. With markets remaining volatile in the first quarter amid economic uncertainty and the trade dispute between the United States and China, companies have been spending on products that help safeguard them from market volatility. Revenue from Nasdaq’s financial technology business climbed 10% from a year ago to $432 million, while revenue at the company’s solutions business rose nearly 9% to $947 million. "The current macro environment, recent policy shifts and ongoing talks about potential tariffs have created significant short-term volatility, and that uncertainty is at this point weighing on global GDP growth expectations," Nasdaq Chair and CEO Adena Friedman said in an analyst call. "Entering the second quarter, this is creating modest impact on the timing of corporate decision-making, although without a meaningful change in overall demand across all economic cycles," she said. Net revenue in the quarter came in at $1.24 billion, above analysts’ expectation of $1.23 billion, according to data compiled by LSEG. Net profit attributable to the company on an adjusted basis was $456 million, or 79 cents per share, in the first quarter ended March 31, compared with $367 million, or 63 cents per share, a year earlier. Analysts on average had expected a profit of 77 cents.

Click Subscribe #Nasdaq #Q1Profit #MarketVolatility #StrongDemand #StockMarket

0 0 0 0

Click Subscribe #ABB #Q1Profit #Robotics #Investing #StockMarket

1 0 0 0

Click Subscribe #Samsung #Q1Profit #ChipSales #Smartphones #TechNews

0 0 0 0